John Morton: The State of Obesity Treatment

Howie and Harlan review the results of a new study testing the effects of anti-obesity medications on cardiovascular health. Then they're joined by Yale's John Morton, a leading bariatric surgeon, to discuss the state of weight-loss surgery and its long-term impact on patients' lives.

Links:

Obesity Drugs

“GLP-1 agonists: Diabetes drugs and weight loss”

“Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes”

“AMA urges insurance coverage parity for emerging obesity treatment options”

“National Coverage Determination: Treatment of Obesity”

“Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States”

“2022 Employer Health Benefits Survey: Section 10 - Plan Funding”

Bariatric Surgery

Mayo Clinic: Bariatric Surgery Overview

John Morton: “Correlating actual one-year weight loss with predicted weight loss by the MBSAQIP: bariatric surgical risk/benefit calculator”

“Outcomes of the Ontario Bariatric Network: a cohort study”

“Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery”

“Weight loss drugs and the push for Medicare coverage”

“Comparative Safety of Sleeve Gastrectomy and Gastric Bypass Up to 5 Years After Surgery in Patients With Severe Obesity”

“A Short History of Bernard Fisher’s Contributions to Randomized Clinical Trials”

“Persistent metabolic adaptation 6 years after The Biggest Loser competition”

“Eligibility for Cardiovascular Risk Reduction Therapy in the U.S. Based on SELECT Trial Criteria: Insights from the National Health and Nutrition Examination Survey”

Read an unedited transcript of this episode.

Learn more about the MBA for Executives program at Yale SOM.

Email Howie and Harlan comments or questions.